Evaluating E-cadherin expression in ovarian surface epithelial tumors: A comprehensive analysis
DOI:
https://doi.org/10.55629/pakjpathol.v36i2.899Abstract
Objective: To evaluate the frequency and pattern of E-cadherin immunoexpression in epithelial ovarian tumors (EOTs) and its association with histological subtypes and tumor grade.
Material and Methods: This descriptive cross-sectional study was conducted in the Department of Pathology at Pakistan Institute of Medical Sciences. A total of 89 histologically confirmed cases of epithelial ovarian carcinoma were included. Immunohistochemistry for E-cadherin was performed, and both staining intensity and the proportion of positively stained tumor cells were assessed. Correlation with tumor subtype and grade was analyzed.
Results: Serous carcinoma was the most common subtype (77.52%), followed by mucinous (13.48%), endometrioid (4.4%), and clear cell carcinoma (4.4%). E-cadherin expression was positive in 56 cases (62.92%) and negative in 33 cases (37.07%). Among serous carcinomas, 66.66% showed positive staining, while 33.3% were negative. Mucinous carcinomas demonstrated E-cadherin positivity in 58.33% of cases. Notably, endometrioid carcinomas showed the highest frequency of E-cadherin loss, with 75% of cases staining negative. Additionally, 50% of clear cell carcinomas lacked E-cadherin expression. A trend of decreasing E-cadherin expression with increasing tumor grade was observed.
Conclusion: Loss of E-cadherin immunoexpression was observed in 37% of epithelial ovarian tumors, with the highest reduction noted in high-grade and endometrioid subtypes. These findings suggest that E-cadherin may serve as a potential prognostic marker in assessing tumor aggressiveness and differentiation in epithelial ovarian carcinomas.
Keywords: Epithelial ovarian cancer, Epithelial ovarian cancer, Endometrioid carcinoma, Mucinous carcinoma.
References
Kostov S, Selçuk I, Watrowski R, Dineva S, Kornovski Y, Slavchev S, et al . Neglected anatomical areas in ovarian cancer: Significance for optimal debulking surgery. Cancers. 2024; 16(2): 285. DOI: https://doi.org/10.3390/cancers16020285
Washington CJ, Karanth SD, Wheeler M, Aduse-Poku L, Braithwaite D, Akinyemiju TF. Racial and socioeconomic disparities in survival among women with advanced-stage ovarian cancer who received systemic therapy. Cancer Causes Control. 2024; 35(3): 487-96. DOI: https://doi.org/10.1007/s10552-023-01810-y
Ibrahim NY, Abdulla SA. Epidemiological assessment of ovarian cancer in some northern Iraqi provinces. Tikrit J Pure Sci. 2021; 26(2): 60-4. DOI: http://dx.doi.org/10.25130/tjps.v26i2.120
Chughtai N, Perveen K, Gillani SR, Abbas A, Chunara R, Manji AA, et al. National cervical cancer burden estimation through systematic review and analysis of publicly available data in Pakistan. BMC Public Health. 2023; 23(1): 834. DOI: https://doi.org/10.1186/s12889-023-15531-z
Kielbik M, Szulc-Kielbik I, Klink M. E-cadherin expression in relation to clinicopathological parameters and survival of patients with epithelial ovarian cancer. Int J Mol Sci. 2022; 23(22): 14383. DOI: https://doi.org/10.3390/ijms232214383
Bose S, Sharma S, Kumar A, Mishra Y, Mishra V. Ovarian cancer and its management through advanced drug delivery system. Medical Oncol. 2025; 42(3):76. DOI: https://doi.org/10.1007/s12032-025-02621-8
Nasser S, El Bairi K, Trapani D, Efared B. Origins and pathology of epithelial ovarian cancer: A brief overview. In Ovarian Cancer Biomarkers, Mapping to Improve Outcomes. 2021: 1-7. DOI: http://dx.doi.org/10.1007/978-981-16-1873-4_1
Kanwal M, Sarfraz T, Tariq H. Histopathological and immunohistochemical evaluation of malignant ovarian tumours. Pak Armed Forces Med J. 2024; 74(1): 26-30. DOI:https://doi.org/10.51253/pafmj.v74i1.5949
Shaik B, Zafar T, Balasubramanian K, Gupta SP. An overview of ovarian cancer: Molecular processes involved and development of target-based chemotherapeutics. Curr Top Med Chem. 2021; 21(4): 329-46. DOI: https://doi.org/10.2174/1568026620999201111155426
Eikenboom EL, van Doorn HC, Dinjens WN, Dubbink HJ, Geurts-Giele WR, Spaander MC, et al. Gynecological surveillance and surgery outcomes in Dutch Lynch syndrome carriers. Cancers. 2021; 13(3): 459. DOI: https://doi.org/10.3390/cancers13030459
Turanjanin D, Stipić N, Stanulović N, Gardić N. Risk factors for peritoneal dissemination of ovarian cancer. Medicinski Pregled. 2023;76(11-12): 331-7. DOI: http://dx.doi.org/10.2298/MPNS2312331T
Fedele M, Sgarra R, Battista S, Cerchia L, Manfioletti G. The epithelial–mesenchymal transition at the crossroads between metabolism and tumor progression. Int J Mol Sci. 2022; 23(2): 800. DOI: https://doi.org/10.3390/ijms23020800
Bindhu DK, Murugan L, Mathews SG, Krishnamurty N, Murali S, Agarwal P, et al. Molecular mavericks: Unveiling the matrix metalloproteinase gene’s role in ovarian cancer. Egyptian J Med Human Genet. 2025; 65: 26. DOI: https://doi.org/10.1186/s43042-025-00693-9
Abdallah MT, Aziz I, Alsammarraie AZ. Estimation of gene expression level of CDH1 as a predisposing factor for metastasis in localized and locally advanced and metastatic breast cancer Iraqi patients. Trends in Immunotherapy. 2023; 7(2): 1-20. DOI: https://doi.org/10.24294/ti.v7.i2.2935
Kani D, Savithri V, Suresh R, Venkitachalam R, Janardhanan M, Aravind T. E-cadherin is a diagnostic biomarker in the progression of oral epithelial dysplasia to squamous cell carcinoma. J Oral Biol Craniofacial Res. 2025; 15(3): 508-14. DOI: https://doi.org/10.1016/j.jobcr.2025.02.015
Pandey I, Misra V, Pandey AT, Verma A. Expression of HER2/neu in gastric adenocarcinoma and its correlation with serum HER2/neu level and E-cadherin expression. Indian J Pathol Microbiol. 2022; 65(1): 35-41. DOI: https://doi.org/10.4103/ijpm.ijpm_133_21
Wang HL, Zhao XK, Zhou FY, Song X, Li LY, Huang GR, et al. Characterization of E-cadherin expression in normal mucosa, dysplasia and adenocarcinoma of gastric cardia and its influence on prognosis. World J Gastrointestinal Oncol. 2022; 14(1): 265-77. DOI: https://doi.org/10.4251/wjgo.v14.i1.265
Sarkar A, Asafudullah SM, Khanam K, Sultana A, Islam N, Sultana S, et al. Histomorphological study of different ovarian lessons in a tertiary care hospital. J Teachers Assoc. 2023; 36(1): 17-22. DOI: https://doi.org/10.3329/taj.v36i1.68275
Xu T, Ding H, Chen J, Lei J, Zhao M, Ji B, et al. Research progress of DNA methylation in endometrial cancer. Biomolecules. 2022; 12(7): 938. DOI: https://doi.org/10.3390/biom12070938
Yang SP, Su HL, Chen XB, Hua L, Chen JX, Hu M, et al. Long-term survival among histological subtypes in advanced epithelial ovarian cancer: Population-based study using the surveillance, epidemiology, and end results database. JMIR Public Health and Surveill. 2021; 7(11): e25976. DOI: https://doi.org/10.2196/25976
Ruiz M, Zhang N, Sood AK, An Z. Antibody therapeutics for epithelial ovarian cancer. Expert Opin Biol Ther. 2022; 22(11): 1379-91. DOI:https://doi.org/10.1080/14712598.2022.2141565
Afridi HK, Zahid NA. Frequency of gynecological malignancies in a tertiary care centre in Karachi, Pakistan. Liaqat National J. 2021; 3(1): 3-6. Available from: https://journals.lnh.edu.pk/lnjcc/pd f/809d5345-c8ee-47b5-9804-5a7de4d768a4.pdf
Chaturvedi M, Krishnan S, Das P, Sudarshan KL, Stephen S, Monesh V, et al. Descriptive epidemiology of ovarian cancers in India: a report from national cancer registry programme. Indian J Gynecol Oncol. 2023; 21(1): 25. DOI: https://doi.org/10.1007/s40944-022-00694-1
Ali SI, Sayyed RH, Akbar SA, Abubakar M, Syed AA. Retrospective study of ovarian malignancy managed in surgical unit at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore. J Pak Med Assoc. 2021;71: 696-8. DOI: https://doi.org/10.47391/jpma.07-727
Song M, Cui M, Liu K. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem. 2022; 232: 114205. DOI: https://doi.org/10.1016/j.ejme ch.2022.114205
Giannini A, Di Dio C, Di Donato V, D’oria O, Salerno MG, Capalbo G, et al. PARP inhibitors in newly diagnosed and recurrent ovarian cancer. Am J Clin Oncol. 2023; 46(9): 414-9. DOI:https://doi.org/10.1097/coc.0000000000001024
Da L, Tarasenko Y, Chen C. Asian American sub-ethnic disparities and trends in epithelial ovarian cancer diagnosis, treatment and survival. Ethn Health. 2024; 29(6): 685-702. DOI: https://doi.org/10.1080/13557858.2024.2359387
Nogueira-Rodrigues A, Giannecchini GV, Secord AA. Real world challenges and disparities in the systemic treatment of ovarian cancer. Gynecol Oncol. 2024; 185: 180-5. DOI: https://doi.org/10.1016/j.ygyno.2024.02.021
Varghese S, Lim MC, Armbrust R, Pareja R, Fotopoulou C. Worldwide barriers of optimal surgical care provision in advanced ovarian cancer. Int J Gynecol Obstet. 2025; 00: 1-9. DOI: https://doi.org/10.1002/ijgo.70033
Collin LJ, Cushing-Haugen KL, Terry KL, Goode EL, Wu AH, Harris HR, et al. Patterns of associations with epidemiologic factors by high-grade serous ovarian cancer gene expression subtypes. Cancer Epidemiol Biomarkers Prev. 2025; 34(5): 762-73. DOI:https://doi.org/10.1158/1055-9965.EPI-24-1143
Davidson NR, Barnard ME, Hippen AA, Campbell A, Johnson CE, Way GP, et al. Molecular subtypes of high-grade serous ovarian cancer across racial groups and gene expression platforms. bioRxiv [Preprint]. 2023 Dec 2:2023.11.01.565179. DOI: https://doi.org/10.1101/2023.11.01.565179
Anitha Das PH, Praseeda I, Sadanandan A. Histopathological spectrum of ovarian tumours in a tertiary care centre in South Kerala, India: A Cross-sectional study. J Clin Diagnostic Res. 2024;18(2): EC21-EC24. DOI: https://doi.org/10.7860/JCDR/2024/67965.19047
Rubtsova SN, Zhitnyak IY, Gloushankova NA. Dual role of E-cadherin in cancer cells. Tissue Barriers. 2022; 10(4): 2005420. DOI:https://doi.org/10.1080/21688370.2021.2005420
Lialios P, Alimperti S. Role of E-cadherin in epithelial barrier dysfunction: implications for bacterial infection, inflammation, and disease pathogenesis. Front Cellular Infect Microbiol. 2025; 15: 1506636. DOI: https://doi.org/10.3389/fcimb.2025.1506636
Kielbik M, Szulc-Kielbik I, Klink M. E-cadherin expression in relation to clinicopathological parameters and survival of patients with epithelial ovarian cancer. Int J Mol Sci. 2022; 23(22): 14383. DOI: https://doi.org/10.3390/ijms232214383
Xu L, Yan X, Wang J, Zhao Y, Liu Q, Fu J, et al. The roles of histone deacetylases in the regulation of ovarian cancer metastasis. Int J Mol Sci. 2023; 24(20): 15066. DOI: https://doi.org/10.3390/ijms242015066
Terada A, Tsuda N, Tasaki S, Park J, Nasu H, Tasaki K, et al. N-myc downstream regulated gene-1 may play an important role in the prognosis of ovarian cancer, in its association with beta-catenin. Kurume Med J. 2022; 69(1.2): 39-46. DOI:https://doi.org/10.2739/kurumemedj.ms6912010
Communal L, Roy N, Cahuzac M, Rahimi K, Köbel M, Provencher DM, et al. A keratin 7 and E-cadherin signature is highly predictive of tubo-ovarian high-grade serous carcinoma prognosis. Int J Mol Sci. 2021; 22(10): 5325. DOI: https://doi.org/10.3390/ijms22105325
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Aisha Pervaiz , Armaghana Qamar Khan, Asma Khattak , Soffia Khursheed, Mehreen Mushtaq , Ramsh Ali
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
